secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2023-06-27T23:59:59+00:00
Accession:  0001157523-23-001035
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aldeyra Phase 2 ADX-629 in chronic cough meets primary safety endpoint; cough frequency significantly reduced vs placebo
--------------------------------------------------------------------------------

- Awake cough frequency reduced vs placebo (P=0.01); 24-hr cough frequency (P=0.001).
- ADX-629 well tolerated; no serious adverse events or discontinuations reported.
- 51 patients enrolled, all completed both treatment periods in crossover design.
- Improvement in LDL and HDL levels observed consistent with prior trials.
- Company to discuss results with regulators; Phase 2 trials in atopic dermatitis and other indications expected 2H 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000115752323001035/0001157523-23-001035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000115752323001035/a53433819.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-001035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer